| Bioactivity | KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC50 of 9.4 nM against KIF18A microtubule-dependent ATPase activity[1]. | ||||||||||||
| Target | IC50: 9.4 nM (KIF18A microtubule-dependent ATPase activity) | ||||||||||||
| Invitro | KIF18A-IN-7 (Compound 22; 7 days) 抑制 JIMT-1、NIH-OVCAR3 和 HCC-15 细胞活力，IC50 分别为 0.0078、0.0097 和 0.011 μM[1]。 Cell Viability Assay[1] Cell Line: | ||||||||||||
| In Vivo | KIF18A-IN-7 (Compound 22; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长[1]。 Animal Model: | ||||||||||||
| Name | KIF18A-IN-7 | ||||||||||||
| CAS | 2914878-00-3 | ||||||||||||
| Formula | C27H35N3O5S2 | ||||||||||||
| Molar Mass | 545.71 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. COGAN, et al. SPIRO INDOLINE INHIBITORS OF KIF18A. Patent WO2023028564. |
KIF18A-IN-7
CAS: 2914878-00-3 F: C27H35N3O5S2 W: 545.71
KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC50 of 9.4 nM against KIF18A microtubule-depende
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.